ClearPoint Neuro Inc vs Gigacloud Technology Inc — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Gigacloud Technology Inc trades at $35.78 (market cap $1.32B). The key difference: Gigacloud Technology Inc is far larger — about 2.8× ClearPoint Neuro Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | GCT | |
|---|---|---|
Market Cap | $478.63M | $1.32B |
Sector | Health | Technology |
52-Week High | $29.60 | $51.80 |
52-Week Low | $8.66 | $20.26 |
Enterprise Value | $506.63M | $1.43B |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
GigaCloud Technology (GCT) trades at $35.40, up 2.88% today, showing strong momentum with consistent earnings beats and robust fundamentals. The stock exhibits a bullish technical signal with key resistance at $36 and support at $34. Recent financials reveal impressive profitability with a 10.77% net income margin and 32.14% ROE, while valuation ratios like P/E of 8.96 suggest potential undervaluation. Positive media coverage highlights growth prospects, including recognition as a 'World Growth Leader' by TIME in June 2026.
Outlook remains positive due to earnings growth and operational efficiency, but risks include market volatility and competitive pressures. Analyst consensus is bullish with 67% buy ratings, supporting upside potential if execution continues. Investors should weigh strong cash flow against sector-specific headwinds for balanced decision-making.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →